Pharmacotherapy in Stress Urinary Incontinence; A Literature Review

Purpose of Review Stress urinary incontinence (SUI) is a commonly observed condition in females, as well as in males who have undergone prostatectomy.

Despite the significant progress made in surgical techniques, pharmacotherapy has not yielded substantial outcomes within the clinical domain.

This review aims to present a comprehensive overview of the existing pharmacotherapy options for stress urinary incontinence (SUI) and the emerging therapeutic targets in this field.

Recent Findings One meta-analysis demonstrated that α-adrenergic medications are more efficacious in improving rather than curing SUI symptoms.

One trial showed reduced pad weight gain with PSD-503, a locally administered α-adrenergic receptor agonist.

New data show that duloxetine’s risk outweighs its benefits.

One small-scale trial was found to support the use of locally administered estriol in improving subjective outcomes.

Emerging targets include serotonin 5HT_2C agonists, selective inhibitors of norepinephrine uptake, and myostatin inhibitors.

Summary Only one of the evaluated drugs, duloxetine, has been approved by some countries.

Currently, trials are evaluating novel targets.

Systemic adverse effects such as gastrointestinal upset with duloxetine and orthostatic hypotension with α -adrenoceptor agonists have hampered the efficacy of drugs used to treat SUI in women and men.